{"filings":[{"id":91018,"accession_number":"0001062822-26-000098","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q1 net loss narrows to $1M on $21.1M revenue; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $21.1M (vs $1.3M), including $20M Novo Nordisk milestone; net loss $1.0M (vs $25.3M).","Cash and investments $199.7M at March 31, 2026; $96.5M stock sale; $100M Hercules loan facility (initial $55M funded).","SONATA-HCM enrollment completion mid-2026; topline results expected Q1 2027.","ZYNQUISTA NDA resubmission for T1D mid-2026; potential approval in 2026.","LX9851 Phase 1 started by Novo Nordisk; $10M milestone earned; up to $1B in total milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":21102000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91017,"accession_number":"0001062822-26-000094","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Lexicon secures $100M loan facility from Hercules Capital; $55M funded at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $55M tranche drawn at closing to repay existing Oxford Finance loan; second $20M and third $25M tranches available subject to milestones.","Interest rate = prime + 3.10% with 9.85% floor; initial 18-month interest-only period extendable to 30 months upon achieving clinical/regulatory milestones.","Loan matures May 4, 2030; secured by first lien on all assets; minimum cash covenant starts June 1, 2027.","Hercules received warrants to buy 691,823 shares at $1.59 per share; additional warrants up to 566,037 shares upon future tranche draws.","Funds support Lexicon's late-stage cardiometabolic pipeline including sotagliflozin HCM trial and potential regulatory filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91016,"accession_number":"0001062822-26-000065","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["3.02","5.02","5.03","5.07","9.01"],"status":"ready","headline":"Lexicon doubles authorized shares to 900M, adopts expanded 2026 equity plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 450M to 900M via Seventh Amended and Restated Certificate of Incorporation.","Stockholders approved 2026 Equity Incentive Plan, raising share reserve from 75M to 90M shares.","2026 Non-Employee Directors' Equity Incentive Plan approved, increasing pool from 4M to 6M shares.","All 408,434.7 shares of Series B Convertible Preferred converted into 20,421,735 common shares.","All director nominees elected and other proposals passed with strong majority votes (e.g., auditor ratification 99.3% for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100894,"accession_number":"0001062822-26-000047","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q4 net loss narrows to $15.5M; cash strengthened with $106.7M added in Feb 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $15.5M ($0.04/share) vs $33.8M loss ($0.09/share) in Q4 2024; full-year loss $50.3M.","Q4 revenue $5.5M including $4.3M licensing from Novo Nordisk and $1.1M INPEFA sales.","Cash, investments, restricted cash $125.2M at Dec 31, 2025; $96.7M capital raise + $10M Novo milestone in Feb 2026.","SONATA-HCM enrollment >50% of 500 patients; on track for mid-2026 completion and Q1 2027 topline.","NDA resubmission for ZYNQUISTA in T1D on track for 2026; positive End-of-Phase 2 meeting for pilavapadin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100893,"accession_number":"0001193125-26-033793","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Lexicon raises ~$94.6M via public offering and private placements; Invus to hold ~51% post-conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 32M shares at $1.30/share raises ~$41.6M gross; underwriters have 30-day option for 4.8M more shares.","Concurrent private placement: 22.4M common shares to Invus at $1.30 for $29.12M; also 184,366 Series B Convertible Preferred shares at $65 each (~$11.98M) convertible into 9.2M common shares.","Additional private placement: Invus buys 182,779 more preferred shares at $65 each for ~$11.88M, convertible into 9.1M common shares; total preferred convertible into ~18.3M common shares.","After conversion of preferred and stockholder approval to increase authorized shares, Invus entities will hold about 51% of outstanding common stock.","Net proceeds to fund continued R&D of drug candidates and for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100892,"accession_number":"0001193125-26-029514","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Lexicon launches public offering, private placement; reports $125.2M cash, Novo milestone, clinical timelines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of common stock launched; Jefferies and Piper Sandler joint book-running managers.","Concurrent private placement to Invus affiliate via preemptive right; option to purchase additional shares pro rata.","Preliminary cash position $125.2M (unaudited) as of year-end 2025; $10M milestone received from Novo Nordisk in Jan 2026.","SONATA-HCM (sotagliflozin) Phase 3 enrollment completion expected mid-2026; topline data Q1 2027.","NDA resubmission for ZYNQUISTA in type 1 diabetes potentially in 2026, supported by STENO1 safety data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117209,"accession_number":"0001193125-25-274383","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lexicon corrects prospectus error on EY internal control audit exemption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement inadvertently stated EY audited internal controls as of Dec 31, 2024.","As a smaller reporting company/non-accelerated filer, Lexicon is exempt from such audit; EY did not perform it.","Correction relates to existing $75M at-the-market equity facility with Jefferies LLC.","No impact on financial statements or current business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117208,"accession_number":"0001193125-25-270020","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lexicon files prospectus supplement for $75M ATM equity facility; no sales to date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for at-the-market offering of up to $75M of common stock through Jefferies LLC.","No shares have been sold under the facility as of November 6, 2025.","Legal opinion from Vinson & Elkins L.L.P. on share validity filed as Exhibit 5.1.","Facility originally established under Open Market Sale Agreement dated December 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117207,"accession_number":"0001062822-25-000049","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q3 2025 net loss narrows to $12.8M; pipeline advances with FDA milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $14.2M (from $1.8M YoY) driven by $13.2M Novo Nordisk licensing; net loss $12.8M vs $64.8M prior year.","Cash and investments $145M as of Sep 30, down from $238M at Dec 31, 2024, but company says strong footing.","End-of-Phase 2 meeting for pilavapadin (DPNP) with FDA scheduled by year-end; partnership discussions ongoing.","LX9851 IND-enabling studies completed and handed to Novo Nordisk; near-term milestone potential $30M.","SONATA-HCM Phase 3 enrollment on target for 2026; 130 sites initiated. Zynquista resubmission feedback expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":44310000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133656,"accession_number":"0001062822-25-000042","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q2 net income of $3.3M vs loss; licensing revenue from Novo Nordisk drives top line","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $28.9M (vs $1.6M Q2'24) driven by $27.5M licensing from Novo Nordisk LX9851 deal.","Net income $3.3M ($0.01 diluted EPS) vs net loss $53.4M ($0.17 loss) in Q2'24.","SG&A expenses fell to $9.4M from $39.2M due to strategic repositioning and reduced INPEFA marketing.","Cash & investments $139M at June 30, 2025, down from $238M at Dec 31, 2024, reflecting severance payments.","Pipeline: pilavapadin partnership talks ongoing; LX9851 IND-enabling on track; SONATA enrollment target for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":30128000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133655,"accession_number":"0001062822-25-000037","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lexicon regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter from Nasdaq on July 23, 2025 confirming compliance with $1 minimum bid price rule.","Matter related to previous failure to meet bid price requirement is now closed.","Common stock (LXRX) continues trading on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133654,"accession_number":"0001062822-25-000035","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lexicon gets Nasdaq 180-day extension to regain $1 bid; stock moves to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted additional 180-day period until Dec 30, 2025 for Lexicon to cure $1 bid price deficiency.","Common stock will transfer from Nasdaq Global Select to Capital Market on July 7, 2025.","Compliance requires closing bid ≥ $1 for ten consecutive business days during the extension period.","Eligibility conditioned on meeting other listing requirements and intent to pursue reverse stock split if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150355,"accession_number":"0001062822-25-000033","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Lexicon shareholders approve reverse stock split authorization (1:10-1:50) and increase equity plan share reserves","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split at ratio 1-for-10 to 1-for-50, at board discretion before 2026 annual meeting.","Equity incentive plan shares increased from 55M to 75M; Non-Employee Directors plan from 2M to 4M.","Directors Raymond Debbane and Ivan H. Cheung elected with >205M and >226M votes for, respectively.","Ernst & Young ratified as independent auditor for FY 2025.","Advisory vote on executive compensation approved with 220.5M for, 7.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150354,"accession_number":"0001062822-25-000027","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q1 net loss narrows to $25.3M; Novo Nordisk license for LX9851, pipeline progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.3M ($0.07/sh) vs $48.4M ($0.20/sh) in Q1 2024; revenue $1.3M.","Cash and investments $194.8M at Mar 31, 2025, down from $238.0M at Dec 31, 2024; includes $7.5M severance.","Exclusive license to Novo Nordisk for LX9851; up to $1B milestones, $75M upfront/near-term payments plus royalties.","Phase 2b PROGRESS study of pilavapadin (DPNP) met objective; 10 mg dose identified for Phase 3.","Operating expenses down ~40% YoY as company transitions to R&D-focused."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1262000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169346,"accession_number":"0001062822-25-000019","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lexicon licenses LX9851 to Novo Nordisk for $45M upfront; amends Oxford loan with $45M prepayment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license to Novo Nordisk for LX9851 (obesity/cardiometabolic); Lexicon receives $45M upfront, eligible for up to $485M regulatory/commercial milestones and $475M sales milestones.","Lexicon entitled to tiered single- to low-double-digit royalties on annual net sales; Novo Nordisk responsible for development and commercialization.","Lexicon amended its Oxford loan, using $45M upfront to prepay $42.06M principal plus $2.94M final payment; prepayment fee waived.","Loan amendment modifies amortization date to May 1, 2027 (or Dec 1, 2026 if certain event fails) and replaces net sales covenant with minimum cash covenant of $29M or 50% of outstanding principal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169345,"accession_number":"0001062822-25-000008","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon reports Q4 net loss $33.8M; pilavapadin 10mg advances to Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $33.8M ($0.09/shr) vs $49.8M loss in Q4 2023; revenue $26.6M including $25M Viatris upfront.","Phase 2b PROGRESS study of pilavapadin met objectives; 10mg dose showed meaningful pain reduction vs placebo; Phase 3 targeting 2025.","Cash and investments $238.0M at Dec 31, 2024, up from $170.0M year-end 2023; full-year net loss $200.4M.","Company ceased active INPEFA promotion and discontinued Zynquista launch prep after FDA CRL; leaner R&D-focused organization.","LX9851 IND on track for 2025; sotagliflozin Phase 3 SONATA HCM trial enrolling with 500-patient target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169344,"accession_number":"0001062822-25-000005","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lexicon Pharmaceuticals receives Nasdaq bid-price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Lexicon on Jan 3, 2025 that bid price closed below $1 for 31 consecutive business days.","Company has until July 2, 2025 to regain compliance by closing at $1+ for 10 consecutive days.","If not cured, Lexicon may seek a second 180-day period if it meets other listing standards; reverse split considered.","Notice does not cause immediate delisting; company will monitor and evaluate options.","No assurance that compliance can be regained or maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169343,"accession_number":"0001062822-25-000003","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lexicon appoints Scott M. Coiante as CFO; base salary $450K, option for 230K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott M. Coiante named SVP and CFO effective Jan 2, 2025; Kristen Alexander remains principal accounting officer.","Base salary $450K; annual cash bonus target 40% of base salary.","Granted option to purchase 230K shares vesting 25% after 1 year then 1/48th monthly.","Coiante previously CFO at Agile Therapeutics and Aprea Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186370,"accession_number":"0001062822-24-000064","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Lexicon cuts workforce 60%, halts commercial ops after FDA setback on ZYNQUISTA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA issued 'deficiencies preclude discussion' letter for ZYNQUISTA (sotagliflozin) NDA in type 1 diabetes and CKD.","Company eliminating commercial operations and reducing workforce by approximately 60%.","Estimated pre-tax charges of $9M–$10.5M for severance and employee costs, mostly cash in Q1 2025.","Company cites need to preserve cash and focus resources on clinical development pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186369,"accession_number":"0001062822-24-000062","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lexicon appoints Ivan Cheung to board as Lefkowitz retires after 23 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert J. Lefkowitz, M.D. retires from board effective Dec 2, 2024; no disagreement cited.","Ivan H. Cheung elected to board effective Dec 2, 2024; will serve on audit committee.","Cheung is CEO of NextPoint Therapeutics, former chairman & CEO of Eisai Inc. (18 yrs).","Cheung receives initial option for 186,685 shares vesting over 3 years plus standard director fees.","Company notes catalyst-rich 2025 and beyond in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186368,"accession_number":"0001062822-24-000057","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q3 net loss $64.8M; ZYNQUISTA PDUFA Dec 20 after negative AdCom vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $64.8M ($0.18/share) vs $50.5M ($0.21) year ago; revenue $1.8M from INPEFA sales.","Licensed sotagliflozin to Viatris for ex-U.S./Europe markets; $25M upfront, up to $197M milestones.","ZYNQUISTA AdCom voted 11-3 that benefits do not outweigh risks; PDUFA target Dec 20, 2024.","INPEFA net sales $1.7M; field force reduced ~50% in September to focus on targeted prescribers.","LX9211 Phase 2b DPNP screening complete, topline data now expected Q1 2025; LX9851 IND on track mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186367,"accession_number":"0001062822-24-000054","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Lexicon licenses sotagliflozin ex-US/Europe to Viatris for $25M upfront plus milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Viatris for sotagliflozin development and commercialization outside US and Europe.","Viatris pays $25M upfront; Lexicon eligible for up to $12M regulatory and $185M sales milestones.","Tiered royalties: low double-digit to upper-teens percentages of net sales in licensed territory.","Lexicon to supply drug under a separate manufacturing and supply agreement with Viatris.","Viatris responsible for regulatory approvals, commercialization, and any additional clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202991,"accession_number":"0001062822-24-000051","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lexicon Pharma CFO/COO Jeffrey Wade to depart Sep 30; Kristen Alexander named principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Wade's employment as president, COO and principal financial officer terminates Sep 30, 2024.","Wade receives salary continuation of $585k for 12 months, lump sum $175.5k, COBRA $3.7k/mo for 12 months, plus outplacement.","Wade enters 8-month consulting agreement at $3,000/month starting after termination.","Kristen Alexander, VP finance and accounting and principal accounting officer since 2021, becomes principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202990,"accession_number":"0001062822-24-000043","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q2 net loss $53.4M; INPEFA sales $1.6M; ZYNQUISTA NDA resubmitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $53.4M ($0.17/sh) vs $44.9M a year ago; cash & investments $310M, up from $170M.","INPEFA (sotagliflozin) net sales $1.6M; commercial launch ongoing.","NDA for ZYNQUISTA in type 1 diabetes resubmitted; PDUFA goal date Dec 20, 2024.","SONATA Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy commenced.","PROGRESS Phase 2b (LX9211) for DPNP topline data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":2777000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202989,"accession_number":"0001062822-24-000036","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lexicon appoints Michael Exton as CEO effective July 8, 2024; Jeffrey Wade promoted to President and COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New CEO Michael Exton, Ph.D., former Novartis cardiometabolism head, to lead Lexicon starting July 8, 2024.","Exton receives $636k base salary, 70% bonus target, and stock option for 1,675,000 shares vesting over 4 years.","Jeffrey Wade promoted from President/CFO to President/COO; base salary increased to $585k, bonus target to 60%.","Wade granted stock option for 307,000 shares vesting over 4 years; also remains principal financial officer.","Severance for Exton: 12 months salary on termination w/o cause; additional one-time bonus target on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202988,"accession_number":"0001062822-24-000032","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lexicon amends Oxford loan: interest-only period to May 2027, maturity to March 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amortization date extended to May 1, 2027; maturity date extended to March 1, 2029.","Final payment percentage increased from prior amount to 7.00% of outstanding principal.","New financial covenant: minimum cash at 50% of outstanding Term Loans through June 30, 2026.","Minimum trailing 6-month net product revenue tied to sNDA approval of sotagliflozin in CKD by March 31, 2025.","Amendment fee paid; existing loan agreement continues in full force except as amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219245,"accession_number":"0001062822-24-000029","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["3.02","5.03","5.07","9.01"],"status":"ready","headline":"Lexicon converts all preferred to 115M common; authorized shares increased to 450M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,304,147 shares of Series A Preferred automatically converted into 115,207,350 common shares on May 10, 2024.","Authorized common stock increased from 300M to 450M via Sixth Amended and Restated Certificate of Incorporation.","Stockholders elected Philippe Amouyal, Lonnel Coats, and Diane Sullivan as Class III directors with >241M votes each.","Ratified charter amendment, approved executive compensation, and reappointed Ernst & Young as auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219244,"accession_number":"0001062822-24-000023","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lexicon Q1 net loss $48.4M; INPEFA sales $1.1M, up 63% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $48.4M ($0.20 per share) vs $31.9M ($0.17) in Q1 2023; SG&A jumped to $32.1M on launch spending.","Revenue of $1.1M from INPEFA (sotagliflozin) heart failure launch; market access ~40%, expansion expected H2 2024.","Cash and investments $355.6M as of March 31, up from $170M due to convertible preferred stock issuance in March.","NDA resubmission for ZYNQUISTA in type 1 diabetes with CKD expected mid-2024; Phase 3 for HCM to start mid-2024.","Enrollment on track for Phase 2b PROGRESS study of LX9211 in DPNP; topline data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":1130000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219243,"accession_number":"0001062822-24-000020","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lexicon CEO Lonnel Coats to retire effective July 7, 2024; board begins CEO search","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lonnel Coats notified retirement as CEO (principal executive officer) and board member, effective July 7, 2024.","Board of directors has initiated a search for a new CEO, considering both internal and external candidates.","No successor named; Coats continues until effective date.","Lexicon Pharmaceuticals (LXRX) trades on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239084,"accession_number":"0001193125-24-065928","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Lexicon files certificate for Series A Convertible Preferred Stock; conversion requires charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each Preferred share converts into 50 common shares upon stockholder approval to increase authorized shares to 450M.","Conversion conditions include approval at 2024 annual meeting, board adoption, and Delaware filing of new charter.","Preferred stockholders vote on as-converted basis on all matters; no separate class vote.","Issuance is part of previously announced private placement; par value $0.01 per share.","Authorized common shares to increase from 300M to 450M under proposed Sixth Amended and Restated Charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239083,"accession_number":"0001193125-24-064310","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","2.02","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Lexicon raises $250M via convertible preferred stock; Q4 net loss widens to $48.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$250M from 2.3M Series A Convertible Preferred shares at $108.50 each, convertible into 115.2M common shares upon stockholder approval of charter increase to 450M shares.","Q4 2023 net loss $48.2M ($0.20 loss per share) vs $30.5M loss in Q4 2022; revenue of $0.7M from INPEFA commercialization.","Full-year 2023 net loss $175.6M ($0.79 loss per share) vs $101.9M in 2022; SG&A increased to $114M, driven by INPEFA launch costs.","Cash and investments $170.0M at Dec 31, 2023; private placement expected to close March 13, 2024.","Pipeline: LX9211 Phase 2b PROGRESS study enrolling; Phase 3 prep for sotagliflozin in HCM and NDA resubmission for type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256576,"accession_number":"0001193125-23-306032","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lexicon enters $75M at-the-market equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $75M of common stock through Jefferies in at-the-market offerings.","Jefferies receives 3.0% commission on gross proceeds; company also reimburses legal fees.","Invus affiliate (largest stockholder) has right to purchase shares to maintain ownership, subject to conditions.","Proceeds intended to fund commercial launch of INPEFA (sotagliflozin), R&D, and working capital.","Shares issued under existing shelf registration; prospectus supplement filed Dec 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256575,"accession_number":"0001062822-23-000060","cik":1062822,"company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lexicon amends Oxford Finance loan; $25M draw tied to INPEFA sales, cash covenant effective immediately","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Minimum cash balance of $10M ($25M if fourth tranche drawn) now immediately effective.","Fourth tranche of $25M available upon specified INPEFA net sales milestones; draw period ends April 15, 2025.","Option to extend interest-only period from 36 to 48 months removed.","Financial covenants now tied to trailing six- or twelve-month INPEFA net product revenue targets per Annex X."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":963906119.5291262,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}